Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Severe Cardiac Allograft Rejection: From Detection to Risk Stratification
Posted inClinical Updates news Pathology & Lab Medicine Transplantation

Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Severe Cardiac Allograft Rejection: From Detection to Risk Stratification

Recent heart-transplant studies show donor-derived cell-free DNA not only detects rejection but also predicts mortality and persistent graft dysfunction, especially when elevated at diagnosis. Evidence supports a shift from binary surveillance toward risk-adapted management.
10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis: What PARTNER 2A Adds to the Long-Term TAVR Evidence Base
Posted inCardiology Clinical Updates news

10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis: What PARTNER 2A Adds to the Long-Term TAVR Evidence Base

The PARTNER 2A 10-year data show higher mortality and reintervention with balloon-expandable SAPIEN XT TAVR versus surgery in intermediate-risk patients, driven mainly by transthoracic access. Contemporary 10-year SAPIEN 3 data, however, suggest outcomes comparable to surgery.